Business
Natera Reports Third Quarter 2021 Financial Results
AUSTIN, Texas, Nov. 4, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in personalized genetic testing, today reported financial results for the
About this update from Natera, Inc.
[{"type":"text","content":"AUSTIN, Texas, Nov. 4, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in personalized genetic testing, today reported financial results for the third quarter ended September 30, 2021 and provided an update on recent business progress and financial outlook.\n\n \n \n \n \n \n \n\n \nRecent Accomplishments & Highlights\nGenerated total revenues of $158.1 million in the third quarter of 2021 compared to $98.1 million in the third quarter of 2020, an increase of 61.1%. Product revenues grew 61.5% over the same period. Processed approximately 407,300 tests in the third quarter of 2021, compared to approximately 262,000 tests processed in the third quarter of 2020, an increase of 55.4%. Secured an exclusive license from Aarhus University to a biobank of up to 40,000 prospectively collected colorectal cancer screening samples for development and validation of a test in early cancer detection. Announced positive results from the Trifecta Study, the largest prospective, multi-site, fully biopsy-matched study ever performed in the kidney transplant space. Launched Prospera™ Kidney with Quantification supported by validation data published in the Journal of the American Society of Nephrology. Announced the validation and launch of the Prospera transplant assessment test in both heart and lung transplant settings: Presented largest prospective validation of a commercial cell-free DNA test in lung transplantation. Prospera Heart data shows excellent performance while maintaining ease of use and minimizing cost to the system.Announced an agreement with NRG Oncology, a National Cancer Institute (NCI)-funded group, to use Signatera® for NRG Oncology's landmark CIRCULATE-US study of MRD-guided treatment in stage II-III colon cancer. Announced new publication in Clinical Cancer Research validating Signatera velocity metric.\"Natera's strong commercial momentum continued in the third quarter and we are pleased to be raising our revenue guidance once again,\" said Steve Chapman, Natera's Chief Executive Officer. \"We are thrilled to be announcing multiple major new features, development programs, and product launches in the transplant and oncology settings.\"\nThird Quarter Ended September 30, 2021 Financial Results \nTotal revenues were $158.1 million in the third quarter of 2021 compared to $98.1 million for the third quarter of 2020,...